A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

Brief Summary

Primary Outcomes

Secondary Outcomes

• Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary(Up to 48 hours)
• Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary(Up to 48 hours)
• Number of participants with chemistry data outside the reference range(Up to 48 hours)
• Number of participants with adverse events (AEs) and serious adverse events (SAEs)(Up to Days 6-14 visit)
• Number of participants with first antiemetic rescue medication(Up to 48 hours)
• The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"(Up to 48 hours)
• The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol(Up to 48 hours)
• Number of participants with first emetic event(Up to 48 hours)
• Number of participants with hematology data outside the reference range(Up to 48 hours)
• Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)(Up to 24 hours)